Evidence map›Paper›PMID 39297458›Full record

ReviewCurrent pharmaceutical design2025

Exploring Hepatocellular Carcinoma Pathogenesis: The Influence of Genetic Polymorphisms.

Samaneh Mollazadeh, Nikoo Saeedi, Abdulridha Mohammed Al-Asady, Elnaz Ghorbani, Majid Khazaei, Mikhail Ryzhikov, Amir Avan, Seyed Mahdi Hassanian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samaneh MollazadehNatural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Nikoo SaeediStudent Research Committee, Islamic Azad University, Mashhad Branch, Mashhad, Iran.
Abdulridha Mohammed Al-AsadyDepartment of Medical Sciences, Faculty of Nursing, Warith Al-Anbiyaa University, Karbala, Iraq.
Elnaz GhorbaniDepartment of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mikhail RyzhikovSchool of Medicine, Saint Louis University, Saint Louis, MO 63103, USA.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is influenced by several factors, among which genetic polymorphisms play a key role. Polymorphisms in various genes affect key pathways involved in HCC development, including metabolism, expression of inflammatory cytokines, cell proliferation, and apoptosis regulation. These polymorphisms induce differential effects on susceptibility to HCC, disease progression, and treatment outcomes. Understanding the effect of genetic variations on HCC pathogenesis is essential to elucidate underlying mechanisms and identify potential therapeutic targets. This review explores the diverse roles of genetic polymorphisms in HCC, providing insights into the complex interplay between genetic factors and disease development.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPolymorphism, GeneticAnimalsGenetic Predisposition to DiseaseHumansapoptosisGeneticshepatocellular carcinoma.liver cancerpolymorphismproliferation

Identifiers

PMID39297458

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.